Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.

e11003 Background: Lapatinib (L) is widely used in patients (pts) with trastuzumab (T)-pretreated HER2-positive metastatic breast cancer (HER2+MBC), although, we do not know upfront use of L is beneficial or not for HER2+MBC pts. Methods: T-pretreated HER2+MBC pts received L plus capecitabine (C). L was administered 1250mg/body daily and C was given 2000mg/m2/day from day 1 to 14 in a 3-week cycle. Clinical efficacy was assessed by 2 (or 3). Results: Thirty female HER2+MBC pts (29 immunohistochemically HER2-positive, 1 FISH-positive), median age of 54 (range 33-72) were treated with L+C. Twenty-four pts (80.0%) had visceral lesion(s) and 8 pts (26.7%) had histories of central nervous system involvement. Median T-based regimens pts received prior to L+C was 2.5 (range 1-7), and 15 pts (50.0%) were heavily (>2) pretreated. Of 23 pts who have complete history of previous therapies, exposed to T from 56 to 2226 (median 876) days prior to L+C. Twenty-two pts discontinued therapy because of disease-progression ...